



ASX ANNOUNCEMENT

Q4 FY26 Results Release Date and Webinar Invitation

Follow our progress:

Did you know that alongside ASX updates, Lumos provides updates across a range of channels?

- To subscribe for all our news delivered to your inbox, please visit <https://lumosdiagnostics.com/invest>.
- Find / follow us on LinkedIn here: www.linkedin.com/company/lumos-diagnostics.

MELBOURNE, Australia (20 July 2026) – Lumos Diagnostics Holdings Ltd (ASX: LDX, “Lumos” or the “Company”) a leader in rapid, point-of-care diagnostic technologies, advises that it intends to release its Quarterly Activity and Cash Flow Report for the three months ended 30 June 2026 (Q4 FY26) on Monday, 27 July 2026.

This will be followed by a webinar for shareholders and investors, on Wednesday, 29 July at 10:15am (AEST).

During the webinar briefing, Chief Executive Officer, Doug Ward, Chief Financial Officer, Barrie Lambert, and Chief Commercial Officer, Paul Kase, will provide an overview of the quarterly results. This will be followed by a Q+A session.

Participants can pre-register ahead of time via the following link:

https://us02web.zoom.us/webinar/register/WN_nYvzMUPJQleS29qe_ngeCQ

Once the registration form is completed, participants will receive a confirmation email with details on how to access the webinar briefing.

In-Person Investor Information Sessions Melbourne/Sydney

Shareholders and investors are reminded that Chair, Sam Lanyon and CEO, Doug Ward will be conducting in-person Investor Information Sessions in Melbourne on Wednesday, 29 July and Sydney on Monday, 3 August 2026, respectively. For further details, please refer to the ASX announcement lodged on 20 July 2026.

-Ends-

This announcement has been approved by the Lumos Disclosure Committee.

About Lumos Diagnostics

Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contacts:

Haley Chartres - Australia
HACK Director
haley@hck.digital
+61 423 139 163

Investor Contact:

George Kopsiaftis
IR Specialist, IR Department
ir@lumosdiagnostics.com
+61 409 392 687

Company Registered Office:

Lumos Diagnostics Holdings Ltd
Suite 2, Level 11
385 Bourke Street
Melbourne VIC 3000
info@lumosdiagnostics.com
+61 3 9087 1598